Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
53.49M | 42.16M | 35.36M | 34.46M | 26.38M | Gross Profit |
25.85M | 21.11M | 19.95M | 17.83M | 14.07M | EBIT |
-5.97M | -12.23M | -20.18M | -19.65M | -18.50M | EBITDA |
-5.97M | -8.71M | -16.77M | -16.89M | -15.87M | Net Income Common Stockholders |
-31.40M | -14.38M | -19.65M | -19.65M | -21.18M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
22.45M | 24.06M | 14.67M | 31.64M | 40.60M | Total Assets |
66.30M | 69.58M | 55.84M | 66.47M | 79.12M | Total Debt |
2.61M | 2.31M | 2.80M | 2.80M | 3.31M | Net Debt |
-13.65M | -18.31M | -11.87M | -28.83M | -37.28M | Total Liabilities |
61.44M | 22.41M | 13.86M | 11.59M | 11.91M | Stockholders Equity |
4.86M | 47.18M | 41.98M | 54.88M | 67.21M |
Cash Flow | Free Cash Flow | |||
-2.43M | -9.89M | -14.97M | -9.32M | -14.16M | Operating Cash Flow |
-2.27M | -9.66M | -14.86M | -8.97M | -13.79M | Investing Cash Flow |
-2.16M | -4.16M | -115.00K | -354.00K | -326.00K | Financing Cash Flow |
78.00K | 19.76M | -1.99M | 361.00K | 50.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $170.66M | 25.50 | 16.56% | ― | 14.85% | 64.96% | |
53 Neutral | $115.49M | ― | -35.68% | ― | 69.17% | 39.01% | |
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
52 Neutral | $166.43M | ― | -304.05% | ― | 28.24% | -334.39% | |
52 Neutral | $173.38M | ― | -76.01% | ― | 25.62% | 11.86% | |
48 Neutral | $169.07M | ― | -52.87% | ― | -4.16% | 12.79% | |
39 Underperform | $52.61M | ― | -94.65% | ― | -5.86% | 50.76% |
On March 23, 2025, LENSAR, Inc. entered into a merger agreement with Alcon Research, LLC, and its subsidiary, VMI Option Merger Sub, Inc., to become a wholly owned subsidiary of Alcon. However, on May 21, 2025, the Federal Trade Commission requested additional information, extending the waiting period for the merger under the Hart-Scott-Rodino Antitrust Improvements Act. LENSAR and Alcon plan to cooperate with the FTC, aiming to complete the merger in the second half of 2025, pending regulatory approval and other conditions.
The most recent analyst rating on (LNSR) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on LENSAR stock, see the LNSR Stock Forecast page.
On March 23, 2025, LENSAR, Inc. entered into a merger agreement with Alcon Research, LLC, where LENSAR will become a wholly owned subsidiary of Alcon. The agreement involves Alcon acquiring all outstanding shares of LENSAR for $14.00 per share in cash, with an additional contingent value right of $2.75 per share based on achieving certain milestones. This acquisition aims to strengthen Alcon’s cataract equipment portfolio and expand the use of LENSAR’s advanced femtosecond laser technology globally. The transaction, valued at up to $430 million, is expected to close in mid-to-late 2025, pending regulatory and stockholder approvals.